Pulse Explore Journal Club Debates Trending Researchers Journals

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Home Explore Journal Club Trending

⌘+K

From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB | Synapse

July 17, 2026JAMA Psychiatry0 citations

View Full Paper

From Schedule I to the Clinic—Insights Into Psychedelic Drug Development From GHB

BBBrian S. BarnettCleveland Clinic Lerner College of Medicine FKFranklin KingHarvard University

Key Points

This viewpoint aims to analyze the regulatory journey of sodium oxybate as a model for psychedelic substances.
Reviewed the regulatory history of sodium oxybate (GHB).
Discussed implications for the development of psychedelics and Schedule I substances.
Sodium oxybate was successfully transitioned from Schedule I to clinical use.
The regulatory pathway highlights potential pathways for psychedelic drug development.

Abstract

This Viewpoint reviews the case of sodium oxybate, a product of gamma-hydroxybutyrate (GHB), to illustrate how psychedelics and other Schedule I substances can proceed through a similar regulatory pathway.

Ask AI

Helpful

Bookmark

Share

View Full Paper

Ask AI

Helpful

Bookmark

Share

View Full Paper

Cite This Study

Barnett et al. (Wed,) studied this question.

synapsesocial.com/papers/6a59c60da58755010b4714dd https://doi.org/https://doi.org/10.1001/jamapsychiatry.2026.1901